broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K30577245-001-05-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.332437 | 4.377529 | 0.790022 | 0.60736 | 0.002074 | 0.002662 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-001024 |
BRD-K31698212-001-02-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.196848 | -0.074888 | -0.004154 | 1 | 0.190802 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-001024 |
BRD-K31928526-001-02-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.46963 | 3.155017 | 0.631758 | 0.864669 | 0.840665 | 2.042709 | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-001024 |
BRD-K33379087-001-07-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.224874 | 0.355 | 0.273601 | 0.724638 | 0.614235 | 3.304826 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-001024 |
BRD-K33610132-001-02-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.69844 | 0.137273 | 0.045758 | 0.835238 | 0.019173 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-001024 |
BRD-K33622447-066-01-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.785536 | 2.320001 | 0.395157 | 0.910392 | 0.17339 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-001024 |
BRD-K35520305-001-16-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.996315 | -0.209122 | -0.068436 | 0.998621 | 0.00545 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-001024 |
BRD-K36627727-001-05-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.990167 | 0.192466 | -0.04696 | 0.993561 | 0.002229 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-001024 |
BRD-K36788280-001-01-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.901085 | 0.154699 | -0.009238 | 0.963551 | 2.976718 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-001024 |
BRD-K37379014-001-02-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.245912 | 4.80279 | 0.658953 | 0.887908 | 0.036876 | 0.042458 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-001024 |
BRD-K38332599-001-01-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.202878 | 5.191271 | 0.805199 | 0.859969 | 1.818096 | 2.009823 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-001024 |
BRD-K38527262-300-01-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.086803 | 3.840054 | 0.818905 | 0.851171 | 1.894162 | 1.990594 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-001024 |
BRD-K38852836-001-02-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.281942 | 1.264883 | 0.873603 | 0.631623 | 0.017228 | 0.033201 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-001024 |
BRD-K39974922-001-04-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.618619 | 0.473438 | 0.258271 | 0.867882 | 0.503576 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-001024 |
BRD-K41859756-001-06-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.347652 | 3.356879 | 0.857563 | 0.610768 | 0.007657 | 0.010909 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-001024 |
BRD-K42495768-001-01-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.203146 | -0.247485 | 0.002296 | 1 | 0.002498 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-001024 |
BRD-K42805893-001-04-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.202486 | 3.98415 | 0.466895 | 0.903849 | 3.111002 | 3.543972 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-001024 |
BRD-K42828737-001-03-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.079369 | -0.298484 | 0.05207 | 1 | 0.097843 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-001024 |
BRD-K42898655-001-01-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.738118 | 0.166616 | 0.111872 | 0.838505 | 0.000242 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-001024 |
BRD-K43389675-001-02-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.101657 | 6.298058 | 0.600708 | 0.741271 | 0.611143 | 0.633603 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-001024 |
BRD-K44227013-001-06-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.12362 | 2.359548 | 0.8313 | 0.76845 | 0.770673 | 0.869249 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-001024 |
BRD-K44408410-001-17-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | -0.073208 | 4.728149 | 0.597449 | 0.975886 | 8.826974 | 8.575612 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-001024 |
BRD-K44827188-001-06-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.512685 | 0.199391 | -0.012062 | 0.903964 | 142.529508 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-001024 |
BRD-K46386702-001-02-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.680581 | -0.007528 | -0.006536 | 0.838815 | 0.909394 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-001024 |
BRD-K49328571-001-15-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.552255 | 0.991511 | 0.38565 | 0.837769 | 0.305894 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-001024 |
BRD-K49350383-001-14-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.998268 | 0.177458 | -0.02284 | 0.999171 | 0.130544 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-001024 |
BRD-K50010139-001-01-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.57479 | 0.515043 | 0.290336 | 0.756614 | 0.033994 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-001024 |
BRD-K50168500-001-07-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.131634 | 4.108307 | 0.671728 | 0.976738 | 8.543026 | 9.202439 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-001024 |
BRD-K51313569-001-07-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.724586 | 0.144589 | -0.033325 | 0.830057 | 0.002527 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-001024 |
BRD-K51791723-003-01-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.089165 | 4.693141 | 0.763468 | 0.750295 | 0.699117 | 0.729003 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001024 |
BRD-K51967704-001-03-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.2954 | 1.298856 | 0.794646 | 0.734046 | 0.258174 | 0.513672 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-001024 |
BRD-K52313696-001-12-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.711846 | 1.225321 | 0.301645 | 0.94485 | 1.705028 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-001024 |
BRD-K53414658-001-08-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.900477 | 0.204133 | -0.007772 | 0.937526 | 0.00494 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-001024 |
BRD-K53972329-001-07-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.886168 | -0.000879 | -0.013878 | 0.941665 | 343,412,249,559,670,000,000,000 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-001024 |
BRD-K54256913-001-08-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.126283 | 5.796664 | 0.599391 | 0.836598 | 1.628458 | 1.712329 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-001024 |
BRD-K54955827-001-02-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.097946 | -3.624311 | 0.071392 | 1 | 0.004885 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-001024 |
BRD-K54997624-001-06-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.488748 | 1.053108 | 0.474084 | 1 | 0.307138 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-001024 |
BRD-K55187425-236-05-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.389426 | 0.807623 | 0.710893 | 0.650162 | 0.03732 | 0.241741 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-001024 |
BRD-K56343971-001-14-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.160875 | -0.303256 | -0.03775 | 1 | 0.774379 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-001024 |
BRD-K56981171-001-02-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.336343 | 0.486416 | 0.171443 | 0.784984 | 0.653195 | 6.489503 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-001024 |
BRD-K57080016-001-15-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.697384 | 1.614227 | 0.708598 | 1 | 0.038265 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-001024 |
BRD-K57169635-001-04-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.067154 | 1.465544 | 0.59338 | 0.854999 | 2.394842 | 2.642504 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-001024 |
BRD-K58435339-001-03-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.428077 | 10.587188 | 0.817537 | 0.714073 | 0.078148 | 0.093855 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-001024 |
BRD-K58529924-001-01-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.987721 | -0.083247 | -0.00954 | 0.993373 | 0.574488 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-001024 |
BRD-K58550667-001-08-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.107466 | 5.207291 | 0.831067 | 0.735992 | 0.035409 | 0.037094 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-001024 |
BRD-K59317601-001-05-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.192489 | 1.22401 | 0.901214 | 0.544901 | 0.041988 | 0.062461 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-001024 |
BRD-K60866521-001-07-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.041603 | -0.135503 | -0.013162 | 1 | 9.626503 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-001024 |
BRD-K60997853-001-02-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.392017 | 3.097309 | 0.512881 | 0.840877 | 0.788815 | 1.293827 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-001024 |
BRD-K61192372-001-08-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.834266 | -0.396013 | 0.091404 | 0.885931 | 0.998461 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-001024 |
BRD-K62008436-001-23-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.323597 | 5.520055 | 0.616209 | 0.690037 | 0.007318 | 0.008838 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-001024 |
BRD-K62196610-001-01-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.914217 | 8.870524 | 0.138206 | 0.971243 | 0.386495 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-001024 |
BRD-K62200014-003-10-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.13066 | 0.826252 | 0.83132 | 0.458389 | 0.022467 | 0.032416 | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-001024 |
BRD-K62391742-001-09-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.062572 | -0.07044 | -0.025065 | 1 | 0.014486 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-001024 |
BRD-K62627508-001-01-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.820407 | 1.704966 | 0.597553 | 1 | 3.473988 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-001024 |
BRD-K64052750-001-22-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.363571 | 3.486186 | 0.506385 | 0.938271 | 3.944404 | 5.7251 | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-001024 |
BRD-K64881305-001-03-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.193445 | 5.68439 | 0.82811 | 0.648148 | 0.145008 | 0.158041 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-001024 |
BRD-K66175015-001-12-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.096771 | 6.327922 | 0.733164 | 0.865883 | 2.366949 | 2.448767 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-001024 |
BRD-K67844266-003-01-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.984449 | -0.06916 | -0.001015 | 0.994457 | 0.000014 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-001024 |
BRD-K69001009-001-02-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.905043 | 0.256022 | -0.009314 | 0.943064 | 0.013276 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-001024 |
BRD-K69694239-001-02-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.123056 | 2.007117 | 0.790616 | 0.662194 | 0.238009 | 0.273981 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-001024 |
BRD-K69776681-001-03-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.295151 | 0.847406 | 0.349596 | 0.607283 | 0.043994 | 0.126101 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-001024 |
BRD-K70301465-001-05-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.340104 | 0.650866 | 0.548252 | 0.803429 | 0.702846 | 4.051227 | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-001024 |
BRD-K70401845-001-15-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.326717 | 12.578985 | 0.630149 | 0.908505 | 2.674554 | 2.909627 | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-001024 |
BRD-K73838513-003-05-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.060593 | 1.493474 | 0.551666 | 0.896174 | 3.977609 | 4.337037 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-001024 |
BRD-K74514084-003-09-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.032679 | -0.192347 | -0.017947 | 1 | 0.007736 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-001024 |
BRD-K75009076-001-02-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | -0.112509 | 4.187554 | 0.486822 | 0.955055 | 7.1129 | 6.776383 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-001024 |
BRD-K76210423-001-01-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.861032 | 7.635547 | 0.049377 | 0.931871 | 0.085854 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-001024 |
BRD-K76239644-001-02-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.714519 | 1.852457 | -0.186922 | 0.816121 | 0.019272 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-001024 |
BRD-K76674262-001-03-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.07585 | 1.0916 | 0.963369 | 0.49236 | 0.048159 | 0.055992 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-001024 |
BRD-K76908866-001-07-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.002283 | -0.062303 | -0.009412 | 1 | 3,686.971004 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-001024 |
BRD-K78431006-001-15-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.934027 | -3.077795 | 0.030699 | 0.941081 | 3.59127 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-001024 |
BRD-K79254416-001-21-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.594513 | 0.183115 | 0.105229 | 0.739481 | 0.002599 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-001024 |
BRD-K81016934-001-02-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.0605 | -0.037886 | -0.00042 | 1 | 677,878.385831 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-001024 |
BRD-K81418486-001-44-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.729382 | 0.23219 | 0.095969 | 0.893051 | 0.588416 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-001024 |
BRD-K81473043-001-19-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | -2.354962 | 5.789244 | 0.473906 | 0.990063 | 0.839606 | 0.621412 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-001024 |
BRD-K82135108-001-04-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.255374 | 1.210211 | 0.606354 | 0.59731 | 0.027687 | 0.049981 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-001024 |
BRD-K82746043-001-19-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.286711 | 0.266808 | -0.019382 | 1 | 21,992.156802 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-001024 |
BRD-K82818427-001-04-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.858619 | 3.605035 | 0.162432 | 0.89093 | 0.005604 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-001024 |
BRD-K83029223-001-01-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.216516 | 3.634425 | 0.722636 | 0.760721 | 0.032256 | 0.037706 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-001024 |
BRD-K83988098-001-02-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.188904 | 1.134495 | 0.541422 | 0.838591 | 0.025106 | 0.038144 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-001024 |
BRD-K85402309-043-01-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.026734 | -0.619656 | -0.020739 | 1 | 0.273589 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-001024 |
BRD-K85606544-001-09-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.337752 | 1.484555 | 0.443581 | 0.801408 | 0.549577 | 1.172952 | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-001024 |
BRD-K86118762-001-01-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.73986 | -1.277607 | 0.0392 | 0.94531 | 0.004419 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-001024 |
BRD-K86972824-001-01-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.93106 | 0.517882 | -0.022786 | 0.975372 | 0.410021 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-001024 |
BRD-K87737963-001-06-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.599665 | 1.822255 | 0.311052 | 0.909216 | 1.118412 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-001024 |
BRD-K87782578-001-01-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.287206 | 1.108725 | 0.679923 | 0.913964 | 4.131148 | 8.926687 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-001024 |
BRD-K87909389-003-03-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.117172 | 2.414039 | 0.877938 | 0.635123 | 0.181163 | 0.202353 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001024 |
BRD-K88510285-001-17-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.191771 | 6.455429 | 0.813774 | 0.615945 | 0.024882 | 0.026818 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-001024 |
BRD-K89014967-001-04-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.411133 | 10.813678 | 0.586426 | 1 | 0.037426 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-001024 |
BRD-K92441787-001-04-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.848176 | -8.993178 | 0.09118 | 0.902407 | 0.312281 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-001024 |
BRD-K92723993-001-17-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.960464 | 3.719758 | 0.022798 | 0.970608 | 0.007357 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-001024 |
BRD-K95142244-001-01-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 45.204774 | 0.244403 | -0.31955 | 1 | 49,201,973,949,213,520,000,000,000,000,000 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-001024 |
BRD-K96123349-236-02-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.727977 | 0.554599 | 0.703611 | 1 | 0.302212 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-001024 |
BRD-K99113996-001-02-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.188922 | 0.911798 | 0.671712 | 0.804079 | 1.099306 | 1.849947 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-001024 |
BRD-K99616396-001-05-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.95096 | -0.362475 | -0.05068 | 0.977817 | 0.040511 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-001024 |
BRD-K99749624-001-07-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.956478 | -5.048593 | 0.020901 | 0.975163 | 0.155067 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-001024 |
BRD-M97302542-001-04-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.089567 | 0.00296 | -0.004964 | 1 | 9,532,755.944113 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-001024 |
BRD-A25234499-001-19-1 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.789418 | 1.372606 | 0.117151 | 0.93994 | 0.638393 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-001075 |
BRD-A70858459-001-01-7 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 1.85237 | 1.466892 | 0.305392 | 1 | 3.288243 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-001075 |
BRD-A74914197-001-02-9 | ACH-001075 | NCIH292_LUNG | MTS010 | 1 | 0.884812 | 10.445952 | 0.134114 | 0.975422 | 0.078802 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-001075 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.